Health Care & Life Sciences » Biotechnology | AMAG Pharmaceuticals Inc.

AMAG Pharmaceuticals Inc. | Ownership

Companies that own AMAG Pharmaceuticals Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
BlackRock Fund Advisors
4,880,456
14.16%
27,030
0.01%
06/30/2018
Palo Alto Investors LP
3,340,806
9.69%
0
3.14%
06/30/2018
Jackson Square Partners LLC
3,183,276
9.23%
3,183,276
0.28%
06/30/2018
The Vanguard Group, Inc.
3,180,114
9.23%
-73,947
0%
06/30/2018
SSgA Funds Management, Inc.
2,705,882
7.85%
36,370
0.01%
06/30/2018
Camber Capital Management LLC
2,650,000
7.69%
0
2.63%
06/30/2018
Armistice Capital LLC
2,080,000
6.03%
176,000
3.86%
06/30/2018
Fidelity Management & Research Co.
1,991,368
5.78%
658,100
0.01%
06/30/2018
Renaissance Technologies LLC
1,641,100
4.76%
96,300
0.04%
06/30/2018
Russell Investment Management LLC
1,170,332
3.4%
415,741
0.05%
06/30/2018

About AMAG Pharmaceuticals

View Profile
Address
1100 Winter Street
Waltham Massachusetts 02451
United States
Employees -
Website http://www.amagpharma.com
Updated 07/08/2019
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the research, development, and commercialization of a therapeutic iron compound to treat iron deficiency anemia. The firm focuses on the development and commercialization of Feraheme injection for intravenous use to treat iron deficiency anemia. It manufactures, develops, and commercializes products derived from its proprietary technology for use in treating human diseases.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.